138 related articles for article (PubMed ID: 16104618)
1. [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey].
Jullien G; Mosnier M; Danchin N
Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):184-9. PubMed ID: 16104618
[TBL] [Abstract][Full Text] [Related]
2. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
[TBL] [Abstract][Full Text] [Related]
3. [Drug prescription in the post-percutaneous coronary interventions period: results of the ECART study].
Philippe F; Sebaoun A; Avierinos C; Julien G
Ann Cardiol Angeiol (Paris); 2004 Jun; 53(3):131-6. PubMed ID: 15291168
[TBL] [Abstract][Full Text] [Related]
4. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
5. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Yahia DH; Pereg D; Lishner M; Elis A
Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
[TBL] [Abstract][Full Text] [Related]
6. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC
Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570
[TBL] [Abstract][Full Text] [Related]
7. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
Kaski JC; Fernandez-Berges D
Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
[TBL] [Abstract][Full Text] [Related]
10. Use of recommended medications after myocardial infarction in Austria.
Winkelmayer WC; Bucsics AE; Schautzer A; Wieninger P; Pogantsch M;
Eur J Epidemiol; 2008; 23(2):153-62. PubMed ID: 18064529
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.
Sharma KK; Mathur M; Gupta R; Guptha S; Roy S; Khedar RS; Gupta N; Gupta R
Indian Heart J; 2013; 65(3):250-5. PubMed ID: 23809376
[TBL] [Abstract][Full Text] [Related]
12. Cardiac medical therapy among patients undergoing abdominal aortic aneurysm repair.
Kurzencwyg D; Filion KB; Pilote L; Nault P; Platt RW; Rahme E; Steinmetz O; Eisenberg MJ
Ann Vasc Surg; 2006 Sep; 20(5):569-76. PubMed ID: 16794911
[TBL] [Abstract][Full Text] [Related]
13. [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Danchin N; Hanania G; Grenier O; Vaur L; Amelineau E; Guéret P; Blanchard D; Ferrières J; Genès N; Lablanche JM; Cantet C; Cambou JP
Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):1-6. PubMed ID: 12710288
[TBL] [Abstract][Full Text] [Related]
14. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
Fox DJ; Kibiro M; Eichhöfer J; Curzen NP
Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208
[TBL] [Abstract][Full Text] [Related]
15. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
[TBL] [Abstract][Full Text] [Related]
16. ACE up the sleeve - are vascular patients medically optimized?
Coveney AP; O'Brien GC; Fulton GJ
Vasc Health Risk Manag; 2011 Jan; 7():15-21. PubMed ID: 21339909
[TBL] [Abstract][Full Text] [Related]
17. Secondary prevention of coronary artery disease in contemporary clinical practice.
Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
19. Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011.
Gitsels LA; Kulinskaya E; Steel N
BMJ Open; 2017 Jan; 7(1):e013570. PubMed ID: 28119386
[TBL] [Abstract][Full Text] [Related]
20. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
Høgh AL
Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
